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Abstract
We have previously shown that a massive increase in global SUMOylation occurs during torpor in ground squirrels, and that
overexpression of Ubc9 and/or SUMO-1 in cell lines and cortical neurons protects against oxygen and glucose deprivation.
To examine whether increased global SUMOylation protects against ischemic brain damage, we have generated transgenic
mice in which Ubc9 is expressed strongly in all tissues under the chicken b-actin promoter. Ubc9 expression levels in 10
founder lines ranged from 2 to 30 times the endogenous level, and lines that expressed Ubc9 at modestly increased levels
showed robust resistance to brain ischemia compared to wild type mice. The infarction size was inversely correlated with
the Ubc9 expression levels for up to five times the endogenous level. Although further increases showed no additional
benefit, the Ubc9 expression level was highly correlated with global SUMO-1 conjugation levels (and SUMO-2,3 levels to a
lesser extent) up to a five-fold Ubc9 increase. Most importantly, there were striking reciprocal relationships between SUMO-
1 (and SUMO-2,3) conjugation levels and cerebral infarction volumes among all tested animals, suggesting that the limit in
cytoprotection by global SUMOylation remains undefined. These results support efforts to further augment global protein
SUMOylation in brain ischemia.
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Introduction
With accelerating discovery of new brain injury mechanisms
(reviewed in: [1,2]) and continuing failure of clinical trials of cell-
based therapies targeting single mechanisms [3], ischemic brain
damage has gradually become more widely viewed as a highly
complex, multifactorial process that involves the interplay of many
non-dominant effectors [4,5]. In order to confront the enormous
biocomplexity of network dynamics in acute stroke and until
Systems Biology provides solutions, our lab focused on broadly
plurifunctional targets that maintain homeostasis in states of
tolerance to brain ischemia. A candidate that meets these criteria is
global SUMOylation, a potentially ‘‘drugable’’ form of post-
translational modification with the Small Ubiquitin-like MOdifer
that appears to have widespread beneficial effects in the dynamic
network, operates in states of tolerance, and acts to preserve
homeostasis under stress [6].
SUMO, like ubiquitin, is synthesized as an inactive precursor,
and processed by SUMO-specific proteases to yield the mature di-
glycine C-terminus. A single heterodimeric E1 activating enzyme
(SAE1/SAE2) initiates conjugation by adenylating SUMO,
followed by the formation of a covalent thioester E1-SUMO
intermediate. SUMO is then transferred to the catalytic cysteine of
the single E2 conjugase, Ubc9 (Ubiquitin conjugase 9), which
alone or in concert with an E3 ligase catalyzes the formation of an
isopeptide linkage between the C-terminal glycine residue of
SUMO and the epsilon-amino group of the substrate lysine
residue. Isopeptidases catalyze de-SUMOylation and thus balance
Ubc9 conjugation activities to modulate steady state levels of
SUMO-conjugates (reviewed in [7,8]). There are three systemi-
cally distributed SUMO paralogs in mammals. Two, SUMO-2
and SUMO-3, are 96% identical in amino acid sequence and are
difficult to distinguish. In contrast, SUMO-1 is only 45% identical
with the other two SUMO paralogs and has distinct immunore-
activity [9].
We initially examined changes in SUMOylation levels during
the hibernation cycle in 13-lined ground squirrels (Spermophilus
tridecemilineatus) that rank among the most brain hypoperfusion-
resistant mammals known [10]. During torpor, these animals
reduce their brain blood flow levels to roughly 10% of baseline
values for up to weeks at a time. Upon arousal, they show no
cellular damage in the brain [10,11,12] despite prolonged brain
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e25852Figure 1. Ubc9 expression levels in WT and Ubc9 transgenic mice. (A) Ubc9 message levels in tail sample from WT and Ubc9 transgenic
founder lines (first generation) were measured in triplicate by real-time PCR. The average Ubc9 mRNA level in each animal was normalized by its
tubulin mRNA level and plotted relative to the WT average level. (B) Ubc9 protein levels in tail samples. Protein (20 mg) isolated from tail samples from
WT and Ubc9 transgenic mice was analyzed by Western blot (upper panel). Intensities of Ubc9 protein bands were normalized to actin and plotted
relative to WT average level (lower panel). n=2–10 (mean6SD). *P,0.05, **P,0.01 (note: G3 n=2 with large SD). (C) Ubc9 protein levels in brain
samples. Proteins (20 mg each) isolated from brains of WT and transgenic mice were analyzed by Western blot (upper panel). Intensities of Ubc9
protein bands were normalized to actin and plotted relative to WT average level (lower panel). n=3–7 (mean6SD). *P,0.05, **P,0.01. (D) Ubc9
expression levels in brain tissue (cerebral cortex, Layer III-external pyramidal region) of WT and Ubc9 transgenic mice (H3, G3). Ubc9 was shown in
red. (E) Ubc9 expressing cells in the cerebral cortex of Ubc9 transgenic mouse (line H3). Upper panels show all layers of cerebral cortex, and lower
panels show an enlarged region of the Layer III-External pyramidal area (dashed rectangle in the upper merged panel). NeuN (green), a pan-neuronal
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zone that is generally regarded as unsalvageable in a stroke. We
found a massive 10- to 30-fold increase in global SUMOylation
(‘‘global’’ here denotes increased band density within a defined
molecular weight range on immunoblots, not that all proteins in
those bands have increased SUMOylation) in many squirrel tissues
during torpor involving both SUMO-1 and SUMO-2/3 paralogs
[14]. Despite suppression of protein translation in hibernating
squirrels to roughly 1/10,000
th of baseline rates [15], levels of the
SUMO conjugase, Ubc9, rose to around three-fold above baseline
during torpor [14]. Additional in vitro ischemia studies conducted
in cell lines and primary cortical neuron cultures exposed to OGD
confirmed that increased global SUMOylation supports cell
survival and OGD tolerance [16]. Ischemic challenge increases
SUMOylation, particularly with SUMO-2,3, in various models:
rat focal ischemia [17,18], mouse focal ischemia [18], rat global
ischemia [19], and in vitro ischemic models [20,21]. It is not yet
clear whether the increase of SUMO-2,3-ylation during ischemic
insults is a result of damage or an active host defense system. At
least, recent data published by Datwyler et al. [22] appears to
support an endogenous neuroprotective impact of SUMO-2,3
conjugation in an in vitro ischemic model.
Based on the foregoing facts and findings, we have now
generated Ubc9 transgenic mice, in which Ubc9 expression is
increased in all tissues at levels that range among the various lines
from 2 to 30 times the endogenous level. Up to five-fold increases
in Ubc9 produced corresponding increases in global SUMO-1 and
SUMO-2,3 conjugation levels. A highly significant inverse
relationship among all transgenic lines was noted in which the
greater were the levels of global SUMOylation, the less was the
extent of infarct damage in the brains of animals exposed to
permanent middle cerebral artery occlusion (pMCAO) for
24 hours.
Results
Generation of Ubc9 transgenic mice
The Ubc9 gene was transferred into mice by pronucleus
injection. Of 98 potential founder animals, Southern blot analysis
revealed 10 animals (B8, F5, F9, G3, H3, K5, J5, L2, N2, N3)
carrying the transgene. The Ubc9 expression (mRNA) levels in tail
samples from these founder lines were analyzed by real-time PCR.
The expression levels varied greatly among these lines as shown in
Figure 1A. Transgenic lines B8 and G3 are the highest Ubc9
expressing lines, followed by L2, F5, N2 and N3, and the rest of
the lines showed only a few-fold increase compare to wild type
animals. Some of the lines (B8, F5, F9, J5 and L2) did not breed
well, and were eventually lost. Inability to breed was not
necessarily correlated with Ubc9 expression level, since one of
the highest Ubc9 expressing line, G3, was still able to breed.
Among surviving lines, we examined Ubc9 protein levels in tail
samples by Western blot. As shown in Figure 1B, the line G3
showed the highest protein expression level followed by lines N3
and H3. The lines N2 and K5 showed only a few-fold increase.
The Ubc9 expression levels in brains (Fig. 1C) among transgenic
lines were very similar to those in tail samples. Similar Ubc9
expression levels were observed in kidneys as well (data not
shown), suggesting that the gene was expressed systemically.
Elevated Ubc9 expression in transgenic mice was also confirmed
by immunostaining of the brain tissue (Fig. 1D). Ubc9 expression
was not only higher, but also more condensed in cell nuclei in
transgenic (H3, G3) mouse brain compared to wild type mouse
brain. Ubc9 was expressed predominantly in neurons (NeuN:
Neuronal Nuclei positive and parvalbumin positive) in the brain
(Fig. 1E shows cerebral cortex and Fig. S1 shows a whole brain
coronal section).
Pathology, physiology and phenotype of Ubc9
overexpression
Six 21-week old animals (3 male and 3 female) each from WT,
low Ubc9 expressing lines (N2, K5 and some of H3) and high
Ubc9 expressing lines (G3 and some of H3) were subjected to
pathology and phenotyping analyses. There are no differences in
hematological analysis or serum chemistry among these animals.
No gross abnormal findings including tumors were noted in any of
the WT mice or in any of the Ubc9 transgenic mice. There were
no significant differences in average blood gas levels between
WT and Ubc9 transgenic (Tg) mice: pH 7.4160.02 (WT),
pH 7.4060.02 (Tg); PCO2 level (mmHg): 42.664.2
(WT), 43.261.9 (Tg); PO2 level (mmHg): 127.0617.6 (WT),
127.1616.0 (Tg). Body temperatures of all animals were between
36.5–37.5 uC. Blood pressure was also monitored during the
surgical procedure, and there was no significant difference
between the average mean arterial blood pressures in WT and
Tg animals: (mmHg): 8366 (WT), 8068 (Tg). There was also no
difference in baseline ipsilateral brain blood flows measured by a
laser doppler perfusion monitor (PERIMED) and expressed as
PeriFlux Units (PU): 103.4621.4 (WT), 97.0635.5 (Tg). Similarly,
the percent reduction of ipsilateral brain blood flows during the
pMCAO surgical procedure did not differ: 7566% (WT), 7765%
(Tg).
Ubc9 transgenic mice are more tolerant to ischemia than
WT mice
Since Ubc9 high-expressing lines, G3 and N3, produced pups
less frequently, we mainly used transgenic lines whose Ubc9 levels
were elevated only several fold (N2, H3, K5) compared to wild
type (WT) animals, but also included a few of the very high
expressing line, G3, for pMCAO surgery. The infarction volumes
in brains from WT and Ubc9 transgenic mice were quantified at
24 h after pMCAO. Typical cresyl violet staining of the 20 micron
coronal brain sections of WT and transgenic mice after 24 h
pMCAO are shown in Figure 2A. Brain infarction volumes were
calculated by summing cross-sectional areas and multiplying these
areas by the distance between the affected sections followed by
correction for brain swelling (edema). The average brain infarction
volumes (mm
3) caused by 24 h pMCAO were 28.466.0 (WT),
17.866.8 (N2), 20.866.5 (H3), 16.864.6 (K5) and 19.364.6 (G3)
(mean6SD) (Fig. 2B). All four transgenic lines (N2, H3, K5, G3)
used in this experiment had significantly smaller average brain
infarctions compared to WT mice. When we plotted infarction
volume (y-axis) against Ubc9 expression level in the brain (x-axis)
for animals that had been subjected to pMCAO, infarction
volumes showed a highly significant inverse correlation with the
Ubc9 expression levels (r, Pearson correlation coeffi-
cient=20.731, p,0.0001), when transgenic animals with Ubc9
expression levels up to a threshold of 5-fold higher than those of
wild type animals were compared (Fig. 2C). Above this threshold,
the correlation was no longer linear.
marker; parvalbumin (purple), a marker for interneurons; GFAP (yellow), a marker for astrocytes; CNPase (blue), a marker for oligodendrocytes. Ubc9i s
shown in red.
doi:10.1371/journal.pone.0025852.g001
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increased in Ubc9 transgenic mice with and without
MCAO
We checked whether the Ubc9 upregulation by the transgene
increases SUMO conjugation levels. The SUMO conjugation
levels, especially the high molecular weight (HMW)
(MW.100 kDa) conjugates, were generally higher in transgenic
mouse lines (N2, H3, K5, G3) compared with WT (representative
immunoblots are shown in Fig. 3A, top panel) (whole immunoblots
are shown in Fig. S2). Densities of Ubc9 protein bands, SUMO-1
HMW conjugates and SUMO-2,3 HMW conjugates in several
immunoblots (n=5 for WT, n=4 for N2, n=5 for H3, n=5 for
K5, n=3 for G3 and n=1 for N3) were measured, normalized by
the corresponding actin levels, and expressed as density relative to
the WT average (Fig. 3A, bottom panel). SUMO-1 HMW
conjugates levels are significantly higher (3,6-fold) in Ubc9
transgenic mice compared with WT, but SUMO-2,3 HMW
conjugates levels were only modestly (2-fold or less) increased in
transgenic mice. After MCAO surgery, not only SUMO-1
conjugation levels, but also SUMO-2,3 conjugation levels in
transgenic mice were significantly higher compared with WT
(representative immunoblots are shown in Fig. 3B top panel, and
density analyses, n=10 for WT, n=8 for N2, N=8 for H3, n=7
for K5 and n=4 for G3, are shown in Fig. 3B bottom panel). The
Western blot data were corroborated by immunohistochemical
studies shown in Figure 3C. Condensed nuclear SUMO-1
(SUMO-2,3 to a lesser extent) expression considered as conjugated
forms [14] was much higher in the brain (both ipsilaterally and
contralaterally) of transgenic mouse (H3) compared to WT. Unlike
WT mice, SUMO-1 as well as SUMO-2,3 and Ubc9 were
expressed uniformly in the whole brain of transgenic mice (Figs.
S3, S4, S5, S6, and S7). The major SUMO-1 and SUMO-2,3
immunoreactive cells in cerebral cortex were predominantly
neurons (NeuN- and Parvalbumin-positive) (Fig. 3C).
SUMO-1 and SUMO-2,3 conjugation levels have a
positive linear correlation with Ubc9 levels and a
negative linear correlation with brain infarction volumes
in WT and Ubc9 transgenic mice
We plotted the Ubc9 protein expression levels against SUMO-1
HMW conjugate levels (Fig. 4A), and against SUMO-2,3 HMW
conjugate levels (Fig. 4B) in the brains of WT and transgenic mice
that had been subjected to 24 h pMCAO. SUMO-1 conjugation
levels have a linear correlation with Ubc9 expression levels
Figure 2. Ubc9 transgenic mice are more tolerant to ischemia than WT mice. (A) Examples of cresyl violet stained coronal brain sections
from WT and Ubc9 transgenic mice (N2, H3, K5 and G3) after 24 h pMCAO. The inset shows an enlarged section with a clear infarcted area for a
precise measurement. (B) Scatter plot of brain infarction volumes in WT (n=12) and Ubc9 transgenic mice, N2 (n=8), H3 (n=10), K5 (n=8) and G3
(n=4) after 24 h pMCAO. Average infarction volume in each animal group is shown as a short horizontal line. *P,0.05, **P,0.01, ***P,0.001. (C) The
brain infarction volumes (y-axis) after 24 h pMCAO are plotted against their Ubc9 protein levels (x-axis). A correlation is seen among animals whose
Ubc9 levels are under 5-fold of wild type. (Pearson correlation coefficient) r=20.713, p,0.0001.
doi:10.1371/journal.pone.0025852.g002
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Top panel: A representative immunoblot of high molecular weight (HMW) (100,300 kDa) conjugates of SUMO-1 and SUMO-2,3 along with Ubc9 and
actin in brain samples from WT and Ubc9 transgenic (N2, H3, N3, K5, G3) mice without MCAO surgery. Bottom panel: Quantitative analysis of Ubc9,
SUMO-1 HMW-conjugates and SUMO-2,3 HMW-conjugates. Intensities were measured, normalized to actin in each sample, and plotted relative to WT
average level. n=3–5 per group (mean6SD; except N3, n=1). *P,0.05, **P,0.01. (B) Comparable immunoblot (top panel) and quantitative analysis
(bottom panel) of Ubc9, SUMO-1 and SUMO-2,3 HMW-conjugates from mice after MCAO surgery. Data are shown as the mean with standard
deviation of 4–10 samples in each animal group. *P,0.05, **P,0.01. (C) Immunofluorescence analysis of SUMO-1 and SUMO-2,3 protein distributions
in infarcted brains. Top row, H&E staining of coronal brain sections from WT and Ubc9 transgenic (H3) mice after 24 h pMCAO. CX, cerebral cortex; CC,
corpus callosum; LV, lateral ventricle; ST, striatum; TH, thalamus; HT, hypothalamus. The second row from the top, comparable coronal brain sections
from WT and H3 mice immunostained for SUMO-1 (red), SUMO-2,3 (yellow), NeuN (green) and parvalbumin (purple). con, contralateral side; ips,
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more than 5-fold increased over the WT level. An increase of more
than 5-fold in Ubc9 level degraded the linear correlation with
SUMO-1 conjugation levels by becoming somewhat inhibitory
(Fig. 4A). SUMO-2,3 conjugation levels showed only a trend
toward a linear correlation with Ubc9 expression level (r=0.321,
p=0.068) (Fig. 4B). Again, Ubc9 expression above 5-fold of the
WT level did not increase SUMO-2,3 conjugation further. When
the SUMO-1 and SUMO-2,3 conjugation levels (x-axis) were
plotted against infarction volumes (y-axis), however, there were
significant inverse linear correlations without any linear disconti-
nuities (r=20.682, p,0.0001 for SUMO-1; r=20.426,
p=0.0133 for SUMO-2,3) (Figs. 4C, D).
Discussion
Ubc9 is the single E2-conjugating enzyme in the SUMO
pathway. We previously showed that Ubc9 levels were well
correlated with SUMO-1 and SUMO-2,3 conjugation levels in
hibernating squirrels and the human neuroblastoma cell line
SHSY5Y, and those with higher SUMO conjugation levels were
more tolerant to ischemic insult [14,16]. In this study, we
established several lines of Ubc9 transgenic mice whose Ubc9
expression levels were elevated globally at various levels (Fig. 1).
These Ubc9 transgenic mice turned out to be significantly more
resistant to pMCAO, an animal stroke model, than corresponding
wild type animals (Fig. 2B). Higher Ubc9 levels in the brain
resulted in lower infarction volumes by pMCAO (Fig. 2C).
However, the linear correlation was lost in high Ubc9 expressing
animals. As we expected, increased Ubc9 levels contributed to the
increase of SUMO-1 and SUMO-2,3 conjugation levels in the
brain. But again, the linear correlation was lost in high Ubc9
expressing animals (Figs. 4A, B), suggesting that Ubc9 levels are
critical for increasing global SUMOylation at low concentrations,
but cease to be a limiting factor above 5–fold the endogenous
baseline where such levels became suppressive.
Figure 4. Correlation of SUMO-1 HMW-conjugates or SUMO-2,3 HMW- conjugates with either Ubc9 level or infarction volume. (A)
The brain SUMO-1 HMW-conjugates level (y-axis) after 24 h pMCAO was plotted against the Ubc9 level (x-axis) in the same sample. Animals whose
Ubc9 levels were under 5-fold the wild type show a significant correlation. (n=42; r: Pearson correlation coefficient=0.713, p,0.0001). (B) The brain
SUMO-2,3 HMW-conjugates level (y-axis) was plotted against the Ubc9 level (x-axis) in the same sample. Animals whose Ubc9 levels were under 5-fold
the wild type show only a trend toward correlation. (n=42; r=0.321, p=0.068). (C) The brain infarction volumes (y-axis) after 24 h pMCAO were
plotted against their SUMO-1 HMW-conjugates levels (x-axis). (n=42; r=20.682, p,0.0001). (D) The brain infarction volumes (y-axis) after 24 h
pMCAO were plotted against their SUMO-2,3 HMW-conjugate levels. (n=42; r=20.426, p=0.0133).
doi:10.1371/journal.pone.0025852.g004
ipsilateral side. Bottom three sets of paired panels show comparable regions of the layer III-external pyramidal area (enlarged from dashed areas in
the upper panels).
doi:10.1371/journal.pone.0025852.g003
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protein Ubiquitination and NEDD (NEural precursor cell-
expressed Developmentally Downregulated-8) ylation have been
shown in vitro [23,24,25]. Recently, an elegant study showed that
a dramatic structural remodeling of the SUMO E1 enzyme (open
form to closed form) takes place during its thioester bond
formation with SUMO protein [26]. Wang et. al. also reported
that at high concentrations SUMO E2 (Ubc9) interacts with the
free E1 heterodimeric enzyme (SAE1/SAE2) and prevents this
conformational change thereby inhibiting SUMO adenylation and
the following SUMO thioester formation [27]. All of these
inhibition studies had been done in in vitro systems. Our results
suggest that inhibition of SUMOylation by high concentrations of
Ubc9 happens in vivo as well.
Although Ubc9 is known to be the only E2 conjugase, there
have been many reports identifying that enzyme as a multifunc-
tional protein that independent of its role as a SUMOylation
conjugating enzyme can act, for example, as a regulator of nuclear
transport [28], a transcriptional co-factor [29,30,31] or a helper
for virus production [32]. Interestingly, the interpretation that
Ubc9 was acting independently of SUMOylation was mostly based
on the effect being found not only for a wild-type Ubc9, but also
for the dominant negative Ubc9 mutant (Ubc9-DN) that was
devoid of E2 conjugase activity [28,29,30,31,32,33,34,35]. Since
Ubc9-DN may also bind to SUMO E1 and inhibit SUMOylation
in the same way as overexpressed Ubc9-WT, the effects observed
may be related to inhibition of SUMOylation and thus not be
independent of the SUMOylation pathway.
Regarding the relationship between global SUMOylation and
brain infarct volumes, the Ubc9 thresholds appear to have little
direct bearing beyond the levels of global SUMOylation that they
catalyze (Figs. 4C, D). Thus, increased global SUMOylation
provides in vivo protection against ischemic brain damage in mice,
although whether the conjugation pattern in transgenic lines is
modified remains to be clarified. In hibernating squirrels, the
SUMO-conjugation levels increased up to 30 times the control
level during the torpor phase, even though Ubc9 levels only
increased 2- to 3-fold [14]. Identifying ways to increase SUMO
conjugation to levels approaching those reached by hibernating
squirrels, which have such extraordinary resistance to blood flow
levels characteristic of a stroke’s ischemic core, is a worthy goal.
We have focused on HMW SUMO conjugation levels in this
study, however, additional data with conditional and tissue specific
interference with Ubc9 or with deconjugating enzymes of SUMO
conjugates would be useful in understanding the physiological
impact of the SUMO system’s neuroprotective effects. SUMOyla-
tion broadly affects the biological network and is involved in many
cellular processes including gene expression, remodeling of
chromatin structure, protein-protein interactions, changes in
protein function, changes in protein intracellular locations, signal
transduction, and maintenance of genome integrity [7,36]. In
general, global SUMOylation is involved in maintenance of
homeostasis under stress [6].
We are investigating various approaches to identify small
molecules that optimize global SUMO conjugation levels in order
to find the limits of the cytoprotection that this plurifunctional
mechanism [6] can deliver. Global SUMOylation is controlled by
a process that is inherently accessible to small molecule regulation
and, as demonstrated by heat shock in which global SUMOylation
(for SUMO-2,3) can be induced within 5 minutes [37], this
putative therapeutic approach could be applied acutely. Further
study of the therapeutic potential of this post-translational
modification of network dynamics is warranted.
Materials and Methods
Plasmid construction
The mouse Ubc9 coding sequence was inserted between the Kpn1
and Xho1 sites of pCCALL2-anton DlacZ ([38] and modified in Dr.
KS Lee’s lab (NCI/NIH)). The Ubc9gene was located under control
of the CMV early enhancer/chicken b-actin (CAG) promoter and
followed by the rabbit b-globin poly adenylation sequence.
Generation of Ubc9 transgenic mice
Ubc9/pCCALL2-anton DlacZ was digested with Sca1 and SfiI
and the fragment containing CMV early enhancer/chicken b-
actin (CAG) promoter, Ubc9 coding sequence and b-globin poly A
sites was purified and injected into fertilized eggs. Founder mice
(C57BL/6 background) were screened for the presence of the
transgene by Southern analysis using BamHI for DNA digestion
and the Ubc9 coding sequence as a
32P-labelled probe. These
transgenic mice were generated by the Laboratory Animal Science
Program in NCI-Frederick.
Genotyping
Mice were marked by ear tags and genotyped by touchdown
PCR on tail DNA prepared by DNeasy Blood & Tissue kit
(Qiagen). Part of the CAG promoter sequence (59-gcgccggcag-
gaaggaaatg-39) was used as a forward primer and part of the Ubc9
coding sequence (59-ggtgatagctggcctccagtcc-39) was used as a
reverse primer. Only the transgene (CAG-Ubc9) is amplified as a
650 bp DNA fragment.
Animals and experimental protocols
The National Institute of Neurological Disorders and Stroke
Animal Care and Use Committee approved all experiments under
the protocol #1268-09 (project title: Use of Ubc9 transgenic mice
for pre-clinical study of stroke). An equal number of male and
female adult mice (18 to 24 weeks old, weight 20 to 30 g) were
used in these experiments. Focal cerebral ischemia was induced in
mice by cauterizing the distal portion of the middle cerebral
artery. A 1.5,2.0 cm skin incision is made between the left eyeball
and ear. Following temporal muscle incision, a craniectomy is
performed at the skull base (2 mm in diameter) to expose,
cauterize and transect the left middle cerebral artery (MCA) and
its anterior branch (if available) at the level above the olfactory
tract. If the brain surface was visibly damaged or if the middle
cerebral artery had bled owing to incomplete artery occlusion/
coagulation, the animal was excluded from the study. The full
MCAO procedure will generally cause an infarction that occupies
about one-third of the ipsilateral hemisphere. At 24 hrs after
surgery, each animal is anesthetized with isoflurane, decapitated
and the brain is promptly removed and frozen for the assessment
of brain damage by histological analysis.
Pathology, physiology, and phenotyping
Six animals (3 male, 3 female) each from WT, low Ubc9
expressing lines and high Ubc9 expressing lines, all of which were
21 weeks old were subjected to pathology and phenotyping
analyses. The analyses were done in the Diagnostic & Research
Service Branch/Office of Director/NIH under the supervision of
Dr. Mark Bryant.
Labeling and imaging of Ubc9, Sumo-1 and Sumo-2, 3
expressions in tissue sections
Mapping Ubc9 expression: Ten mm thick mouse brain coronal
sections were immunoreacted for 1 hour at room temperature
SUMOylation in Ischemic Tolerance
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rabbit IgG anti-Ubc9 (Abcam), chicken IgG (IgY) anti-GFAP
(Abcam) to identify astrocytes, mouse IgG1 anti-CNPase (Milli-
pore) to identify oligodendrocytes, and guinea pig IgG anti-
parvalbumin (Synaptic Systems) to identify interneurons. The
sections were then washed in PBS/BSA and immunoreacted using
a1 mg/ml mixture of the following fluorochrome-conjugated
secondary antibodies: goat anti-rabbit IgG-Alexa Fluor 700, goat
anti-chicken IgG (IgY)-Alexa Fluor 594, goat anti-mouse IgG1-
Alexa Fluor 350 (all from Invitrogen) and donkey anti-guinea pig
IgG-IRDye 800CW (Li-Cor Biosciences). After rinsing excess
secondary antibodies, the potentially unbound F(ab9)2 antigen
binding sites on the goat anti-mouse IgG1-Alexa Fluor 350
secondary antibody were blocked using 30 minute incubation at
RT in 5 mg/ml unlabeled mouse IgG1 antibody purified from
non-immunized mouse serum (Bethyl Laboratories) and the
sections then stained with 1 mg/ml Alexa Fluor 488-conjugated
mouse IgG1 anti-NeuN (Millipore), a pan-neuronal marker. The
slides with labeled tissue sections were then coverslipped using
Immu-Mount medium (Thermo Fisher Scientific) and imaged
using a multi-channel wide field fluorescence microscope (see
below).
Mapping Sumo-1 and Sumo-2, 3 expressions: The immunostaining
protocol for Sumo-1 and Sumo-2, 3 was essentially the same as
detailed above for Ubc9 immunostaining with the following
modification: rabbit IgG anti-Sumo-1 (in-house developed anti-
body) was used instead of rabbit IgG anti-Ubc9 and rat IgG2a
anti-Sumo-2, 3 (Sigma-Aldrich) was included in the primary
antibody mixture, which was subsequently visualized using goat
anti-rat Alexa Fluor 546 (Invitrogen).
Imaging of immunofluorescence reactions: All sections were imaged
using a Axiovert 200M fluorescence microscope (Carl Zeiss)
equipped with a 206 Plan-Apochromat (Phase-2) objective (Carl
Zeiss), a high resolution ORCA-ER cooled digital camera
(Hamamatsu Photonics) sensitive to a wide-spectrum of emission
wavelengths, including those approaching infrared, a 100W
mercury arc lamp (Carl Zeiss), and excitation/dichroic/emission
filter sets (Semrock) optimized to detect the following fluorophores:
Alexa Fluor 350, Alexa Fluor 488, Alexa Fluor 546, Alexa Fluor
594, Alexa Fluor 700 and IRDye 800CW. Each labeling reaction
was captured using filtered light through an appropriate
fluorescence filter set and the images individually digitized at 12-
bit resolution using the Volocity imaging program (Improvision).
An appropriate color table was applied to each image to either
match its emission spectrum or to set a distinguishing color
balance. The pseudocolored images were then converted into
TIFF files, exported to Adobe Photoshop and overlaid as
individual layers to create multi-colored merged composites.
Cresyl violet staining
Frozen brain coronal sections (20 mm) from operated (24 h after
MCAO) wild type and Ubc9 transgenic mice were fixed with
paraformaldehyde vapor overnight. The sections on slides were
treated with ethanol (30 min), hydrated sequentially (100%
ethanol, 95% ethanol, 70% ethanol, and H2O), and stained with
0.5% cresyl violet in H2O/acetic acid for 6 min. After washing
with H2O, the sections were dehydrated sequentially (75%
ethanol, 95% ethanol, 100% ethanol, Histoc-Clear) and mounted
with cover slide for longer storage.
Assessment of infarct volumes
Quantification of the infarct area was performed on the cresyl-
violet-stained sections (20 mm thickness and every 0.34 mm
interval). The infarct area of each section was measured using
the NIH Image J program, and corrected for the effect of edema
by the following equation [39]: Corrected infarct area=infarct
area6area of contralateral hemisphere/area of ipsilateral hemi-
sphere. Infarct volume (mm
3) was calculated for each animal by
integrating the corrected infarct area with the distance between
sections (0.34 mm) [40].
Real-time PCR
Total RNA was isolated from tail or brain tissues of WT and
transgenic mice by Trizol and RNeazy RNA isolation kit (Qiagen).
In a given experiment, the same amount of RNA was used from
each sample. The real-time PCR was performed by the one-step
method using the QuantiTect SYBR Green RT-PCR Master Mix
together with the QuantiTect RT Mix (Qiagen), according to the
manufacturer’s protocol. The mRNA level of Ubc9 was
normalized with b-tubulin (using the Tubb4 primer set, Qiagen)
as an internal control. The primers used for Ubc9 were sense 59-
gatgactatccgtcctcaccacc and antisense 59-ggtgatagctggcctccagtcc.
The delta Ct (threshold cycle) value (DCt) in each sample was
normalized by the formula DCt=Ct Ubc92Ct tubulin. The fold
change was calculated as (=2
2DDCt), where DDCt was the
difference between a given sample and a wild type sample
(=DCt sample2DCt wild type).
Western blot analysis
Frozen brains, kidneys or tails were crushed on dry ice to make
powder, added to 2% SDS, 60 mM Tris-HCl (pH 6.8), 50 mM
EDTA, protease inhibitor cocktail (Roche), 1 mM PMSF (Sigma)
and 20 mM N-ethylmaleimide (Sigma), and homogenized either
by MagNA Lyser (Roche) for 2 cycles of 6500 rpm650 sec, or a
tissue homogenizer for 10 sec. The homogenates were sonicated
for 10 sec, heated for 10 min at 95uC and centrifuged at 15,000g
for 10 min at 4uC. After the protein concentration was measured,
the supernatant was heated again at 95uC for 5 min with 5% b-
mercaptoethanol and 2% glycerol, and subjected (20 mg/lane) to
SDS-PAGE (4% to 20% in Tris-glycine). Western blot analyses
were performed using the following antibodies: rabbit monoclonal
anti-Ubc9 (abcam), rabbit polyclonal anti-SUMO-1 and anti-
SUMO-2/3 antibodies (both antibodies developed in-house), and
mouse monoclonal anti-b-actin antibodies (Sigma). Intensities of
bands were analyzed by the densitometry program ImageJ (NIH).
For SUMO conjugates band analysis, the higher molecular weight
area (100 ,300 kDa) in each lane was cropped and analyzed.
Statistics
The independent two sample t-test was used to compare the
means of two groups of interest. Correlation between two variables
of interest was obtained by using Pearson’s correlation coefficient.
All statistical analyses were performed by means of SAS (SAS
institute Inc., Cary, NC) and all reported p-values are two-tailed.
The significance level was P,0.05.
Supporting Information
Figure S1 Distribution of Ubc9 expression and locali-
zation in a whole brain section. A whole coronal section of
Ubc9 transgenic mouse brain (line H3) was immunostained for
Ubc9 (red) and the following neuronal and glial markers: NeuN
(green), a pan-neuronal marker; parvalbumin (purple), a marker
for interneurons; GFAP (yellow), a marker for astrocytes; CNPase
(blue), a marker for oligodendrocytes. Upper panel shows a whole
brain section with all five immunostainings together. The bottom
panels are enlarged images of cerebral cortex region (dashed
boxed area in the top panel) showing individual cell types with
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with astrocytes and oligodendrocytes exhibiting low expression
levels of this protein.
(TIF)
Figure S2 SUMO-1 and SUMO-2,3 conjugation levels in
the brain from WT and Ubc9 transgenic mice with and
without MCAO. Representative immunoblots of whole SUMO-
1 and SUMO-2,3 protein patterns in the brain extracts from the
WT and transgenic mice without MCAO surgery (A) or that had
been subjected to 24 h pMCAO (B). The top panels show Ubc9
levels and the bottom panels show actin levels.
(TIF)
Figure S3 Distribution of neuronal cells in a whole
coronal section of WT and Ubc9 transgenic (H3) mice
that had been subjected to 24 h pMCAO. NeuN (green), a
pan-neuronal marker; parvalbumin (purple), a marker for
interneurons.
(TIF)
Figure S4 Distribution and intensity of SUMO-1 (con-
jugated and free form) in a whole coronal section of WT
and Ubc9 transgenic (H3) mice that had been subjected
to 24 h pMCAO.
(TIF)
Figure S5 Distribution and intensity of SUMO-2,3
(conjugated and free form) in a whole coronal section
of WT and Ubc9 transgenic (H3) mice that had been
subjected to 24 h pMCAO.
(TIF)
Figure S6 Merged with NeuN (green), parvalbumin
(purple), SUMO-1 (orange), and SUMO-2,3 (yellow) in
a whole coronal section of WT and Ubc9 transgenic (H3)
mice that had been subjected to 24 h pMCAO.
(TIF)
Figure S7 Distribution and intensity of Ubc9 in a whole
coronal section adjacent to the above (Figures S3, S4, S5,
S6) of WT and Ubc9 transgenic (H3) mice that had been
subjected to 24 h pMCAO.
(TIF)
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